Cover Image
Market Research Report
Product code 
1036101

Acute Graft Versus Host Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Published: | Transparency Market Research | 217 Pages | Delivery time: 1-2 business days

Price

Back to Top
Acute Graft Versus Host Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031
Published: July 30, 2021
Transparency Market Research
Content info: 217 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

Acute Graft Versus Host Disease (GvHD) Treatment Market - Scope of Report

TMR's report on the global acute graft versus host disease (GvHD) treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market over the forecast period from 2021 to 2031. The report provides the overall revenue of the global acute graft versus host disease (GvHD) treatment market for the period from 2017-2031, considering 2020 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR) of the global acute graft versus host disease (GvHD) treatment market for the forecast period of 2021-2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the global acute graft versus host disease (GvHD) treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various phenomena in the global acute graft versus host disease (GvHD) treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the acute graft versus host disease (GvHD) treatment market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the acute graft versus host disease (GvHD) treatment market.

The report also delves into the competitive landscape of the global acute graft versus host disease (GvHD) treatment market. Key players operating in the global acute graft versus host disease (GvHD) treatment market have been identified and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the acute graft versus host disease (GvHD) treatment market profiled in this report.

Key Questions Answered in Acute Graft Versus Host Disease (GvHD) Treatment Market Report

How does the development of acute graft versus host disease (GvHD) treatment provide scope of growth in the global acute graft versus host disease (GvHD) treatment market?

How alliances and partnerships between players are widening the scope of new line of therapies for acute graft versus host disease (GvHD) treatment?

What are the revenue share projections of key segments under various criteria in the acute graft versus host disease (GvHD) treatment market during the forecast period?

Which segment is likely to register highest revenue until the end of the forecast period in 2031?

How is the evolving healthcare system in developing countries in Asia Pacific making an impact on the overall acute graft versus host disease (GvHD) treatment market?

Acute Graft Versus Host Disease (GvHD) Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global acute graft versus host disease (GvHD) treatment market begins with an overview of the market, followed by the scope and objectives of this study. Following this, the report provides detailed explanation of the objectives behind this study and healthcare compliances laid down by accredited agencies in purview of line of procedure for acute graft versus host disease (GvHD) treatment.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global acute graft versus host disease (GvHD) treatment market in terms of drug class, route of administration, distribution channel, and region. Key segments under each criteria are studied at length and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global acute graft versus host disease (GvHD) treatment market.

Table of Contents
Product Code: TMRGL82607

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Acute Graft Versus Host Disease (GvHD) Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definitions
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. COVID-19 Pandemics Impact on Industry (value chain and short / mid / long term impact)
  • 5.2. Key Industry Events
  • 5.3. Pipeline Analysis
  • 5.4. Overview of Companies Offering stem cell treatment and/or Treg cell treatment for Acute Graft Versus Host Disease (GvHD)
  • 5.5. Treatment and Management of Acute Graft Versus Host Disease (aGvHD)

6. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Drug Class, 2017-2031
    • 6.3.1. Corticosteroids
    • 6.3.2. Immunosuppressive Agents
    • 6.3.3. Biological Therapy
    • 6.3.4. Kinase Inhibitors
    • 6.3.5. Monoclonal Antibody
    • 6.3.6. Mesenchymal Stem Cell (MSC)
    • 6.3.7. Others
  • 6.4. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Drug Class

7. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast, by Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Route of Administration, 2017-2031
    • 7.3.1. Oral
    • 7.3.2. Topical
    • 7.3.3. Intravenous
  • 7.4. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Route of Administration

8. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Distribution Channel, 2017-2031
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Distribution Channel

9. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Country/Region

10. North America Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Drug Class, 2017-2031
    • 10.2.1. Corticosteroids
    • 10.2.2. Immunosuppressive Agents
    • 10.2.3. Biological Therapy
    • 10.2.4. Kinase Inhibitor
    • 10.2.5. Monoclonal Antibody
    • 10.2.6. Mesenchymal Stem Cell (MSC)
    • 10.2.7. Others
  • 10.3. North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Route of Administration, 2017-2031
    • 10.3.1. Oral
    • 10.3.2. Topical
    • 10.3.3. Intravenous
  • 10.4. North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. North America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis
    • 10.6.1. By Drug Class
    • 10.6.2. By Route of Administration
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Drug Class, 2017-2031
    • 11.2.1. Corticosteroids
    • 11.2.2. Immunosuppressive Agents
    • 11.2.3. Biological Therapy
    • 11.2.4. Kinase Inhibitors
    • 11.2.5. Monoclonal Antibody
    • 11.2.6. Mesenchymal Stem Cell (MSC)
    • 11.2.7. Others
  • 11.3. Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Route of Administration, 2017-2031
    • 11.3.1. Oral
    • 11.3.2. Topical
    • 11.3.3. Intravenous
  • 11.4. Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis
    • 11.6.1. By Drug Class
    • 11.6.2. By Route of Administration
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Drug Class, 2017-2031
    • 12.2.1. Corticosteroids
    • 12.2.2. Immunosuppressive Agents
    • 12.2.3. Biological Therapy
    • 12.2.4. Kinase Inhibitors
    • 12.2.5. Monoclonal Antibody
    • 12.2.6. Mesenchymal Stem Cell (MSC)
    • 12.2.7. Others
  • 12.3. Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Route of Administration, 2017-2031
    • 12.3.1. Oral
    • 12.3.2. Topical
    • 12.3.3. Intravenous
  • 12.4. Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. Japan
    • 12.5.2. China
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis
    • 12.6.1. By Drug Class
    • 12.6.2. By Route of Administration
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Drug Class, 2017-2031
    • 13.2.1. Corticosteroids
    • 13.2.2. Immunosuppressive Agents
    • 13.2.3. Biological Therapy
    • 13.2.4. Kinase Inhibitors
    • 13.2.5. Monoclonal Antibody
    • 13.2.6. Mesenchymal Stem Cell (MSC)
    • 13.2.7. Others
  • 13.3. Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Route of Administration, 2017-2031
    • 13.3.1. Oral
    • 13.3.2. Topical
    • 13.3.3. Intravenous
  • 13.4. Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis
    • 13.6.1. By Drug Class
    • 13.6.2. By Route of Administration
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Drug Class, 2017-2031
    • 14.2.1. Corticosteroids
    • 14.2.2. Immunosuppressive Agents
    • 14.2.3. Biological Therapy
    • 14.2.4. Kinase Inhibitors
    • 14.2.5. Monoclonal Antibody
    • 14.2.6. Mesenchymal Stem Cell (MSC)
    • 14.2.7. Others
  • 14.3. Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Route of Administration, 2017-2031
    • 14.3.1. Oral
    • 14.3.2. Topical
    • 14.3.3. Intravenous
  • 14.4. Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis
    • 14.6.1. By Drug Class
    • 14.6.2. By Route of Administration
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (by tier and size of companies)
  • 15.2. Market Ranking, by Company, 2020
  • 15.3. Company Profiles
    • 15.3.1. Bristol-Myers Squibb
      • 15.3.1.1. Company Description
      • 15.3.1.2. Business Overview
      • 15.3.1.3. Strategic Overview
      • 15.3.1.4. SWOT Analysis
    • 15.3.2. Novartis AG
      • 15.3.2.1. Company Description
      • 15.3.2.2. Business Overview
      • 15.3.2.3. Strategic Overview
      • 15.3.2.4. SWOT Analysis
    • 15.3.3. Mesoblast Ltd
      • 15.3.3.1. Company Description
      • 15.3.3.2. Business Overview
      • 15.3.3.3. Strategic Overview
      • 15.3.3.4. SWOT Analysis
    • 15.3.4. Equillium, Inc.
      • 15.3.4.1. Company Description
      • 15.3.4.2. Strategic Overview
      • 15.3.4.3. SWOT Analysis
    • 15.3.5. Cynata Therapeutics Limited
      • 15.3.5.1. Company Description
      • 15.3.5.2. Business Overview
      • 15.3.5.3. Strategic Overview
      • 15.3.5.4. SWOT Analysis
    • 15.3.6. MaaT Pharma
      • 15.3.6.1. Company Description
      • 15.3.6.2. Strategic Overview
      • 15.3.6.3. SWOT Analysis
    • 15.3.7. Incyte Corporation
      • 15.3.7.1. Company Description
      • 15.3.7.2. Business Overview
      • 15.3.7.3. Strategic Overview
      • 15.3.7.4. SWOT Analysis
    • 15.3.8. Xenikos B.V.
      • 15.3.8.1. Company Description
      • 15.3.8.2. Strategic Overview
      • 15.3.8.3. SWOT Analysis
    • 15.3.9. Merck & Co. (OncoImmune, Inc.)
      • 15.3.9.1. Company Description
      • 15.3.9.2. Business Overview
      • 15.3.9.3. Strategic Overview
      • 15.3.9.4. SWOT Analysis
    • 15.3.10. medac GmbH
      • 15.3.10.1. Company Description
      • 15.3.10.2. SWOT Analysis
    • 15.3.11. CSL Limited
      • 15.3.11.1. Company Description
      • 15.3.11.2. Business Overview
      • 15.3.11.3. SWOT Analysis

List of Tables

  • Table 01: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031 (1/2)
  • Table 02: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031 (2/2)
  • Table 03: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 04: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 05: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 06: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 07: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 08: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 09: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 10: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 11: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 12: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 13: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 14: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 15: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 16: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 17: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 18: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 19: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 20: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 21: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 22: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 23: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 24: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 25: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

  • Figure 01: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share, by Drug Class, 2020
  • Figure 03: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share, by Route of Administration, 2020
  • Figure 04: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share, by Distribution Channel, 2020
  • Figure 05: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share, by Region, 2020
  • Figure 06: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Drug Class, 2020 and 2031
  • Figure 07: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Drug Class, 2021-2031
  • Figure 08: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Corticosteroids, 2017-2031
  • Figure 09: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Immunosuppressive Agents, 2017-2031
  • Figure 10: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Biological Therapy, 2017-2031
  • Figure 11: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Kinase Inhibitors, 2017-2031
  • Figure 12: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Monoclonal Antibody, 2017-2031
  • Figure 13: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Mesenchymal Stem Cell, 2017-2031
  • Figure 14: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 15: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031
  • Figure 16: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Route of Administration, 2021-2031
  • Figure 17: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Oral, 2017-2031
  • Figure 18: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Topical, 2017-2031
  • Figure 19: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Intravenous, 2017-2031
  • Figure 20: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2031
  • Figure 21: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2021-2031
  • Figure 22: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Hospital Pharmacies, 2017-2031
  • Figure 23: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Retail Pharmacies, 2017-2031
  • Figure 24: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Online Pharmacies, 2017-2031
  • Figure 25: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Region, 2020 and 2031
  • Figure 26: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Region, 2021-2031
  • Figure 27: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 28: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Country, 2020 and 2031
  • Figure 29: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Country, 2021-2031
  • Figure 30: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Drug Class, 2020 and 2031
  • Figure 31: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Drug Class, 2021-2031
  • Figure 32: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031
  • Figure 33: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Route of Administration, 2021-2031
  • Figure 34: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2031
  • Figure 35: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2021-2031
  • Figure 36: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 37: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
  • Figure 38: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
  • Figure 39: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Drug Class, 2020 and 2031
  • Figure 40: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Drug Class, 2021-2031
  • Figure 41: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031
  • Figure 42: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Route of Administration, 2021-2031
  • Figure 43: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2031
  • Figure 44: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2021-2031
  • Figure 45: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 46: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
  • Figure 47: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
  • Figure 48: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Drug Class, 2020 and 2031
  • Figure 49: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Drug Class, 2021-2031
  • Figure 50: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031
  • Figure 51: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Route of Administration, 2021-2031
  • Figure 52: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2031
  • Figure 53: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2021-2031
  • Figure 54: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 55: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
  • Figure 56: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
  • Figure 57: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Drug Class, 2020 and 2031
  • Figure 58: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Drug Class, 2021-2031
  • Figure 59: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031
  • Figure 60: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Route of Administration, 2021-2031
  • Figure 61: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2031
  • Figure 62: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2021-2031
  • Figure 63: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 64: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
  • Figure 65: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
  • Figure 66: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Drug Class, 2020 and 2031
  • Figure 67: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Drug Class, 2021-2031
  • Figure 68: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031
  • Figure 69: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Route of Administration, 2021-2031
  • Figure 70: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2031
  • Figure 71: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2021-2031
  • Figure 72: Market Position Analysis, by Tier and Size of Company
  • Figure 73: Bristol-Myers Squibb Revenue (US$ Mn) and Y-o-Y Growth (%), 2017 -2020
  • Figure 74: Bristol-Myers Squibb Breakdown of Net Sales (%), by Region/Country, 2020
  • Figure 75: Bristol-Myers Squibb R&D Expenses (US$ Mn) 2017-2020
  • Figure 76: Novartis AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2020
  • Figure 77: Novartis AG Breakdown of Net Sales (%), by Region/Country, 2020
  • Figure 78: Novartis AG Revenue Breakdown of Net Sales (%), by Business Segment, 2020
  • Figure 79: Novartis AG R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017-2020
  • Figure 80: Mesoblast Ltd. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017-2020
  • Figure 81: Mesoblast Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2020
  • Figure 82: Cynata Therapeutics Limited Business Overview
  • Figure 83: Incyte Corporation Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2020
  • Figure 84: Incyte Corporation JAKAFI Revenue (US$ Mn) and Y-o-Y Growth (%), 2018-2020
  • Figure 85: Incyte Corporation R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017-2020
  • Figure 86: Merck & Co. Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2020
  • Figure 87: Merck & Co. Breakdown of Net Sales (%), by Region/Country, 2020
  • Figure 88: Merck & Co. Revenue Breakdown of Net Sales (%), by Business Segment, 2020
  • Figure 89: Merck & Co. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017-2020
  • Figure 90: CSL Limited Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2020
  • Figure 91: CSL Limited Breakdown of Net Sales (%), by Region/Country, 2020
  • Figure 92: CSL Limited Revenue Breakdown of Net Sales (%), by Business Segment, 2020
  • Figure 93: CSL Limited R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018-2020